Caracterización y resultados del uso de voriconazol nebulizado en un entorno real: un estudio observacional unicéntrico / Characterization and real-live results of nebulized voriconazole: A single-center observational study

Objetivo la administración de voriconazol nebulizado implica ventajas, incluyendo la optimización de la penetración pulmonar y la reducción de los efectos adversos e interacciones; sin embargo, la evidencia sobre su utilización es escasa y no existen presentaciones comerciales específicas para nebulización. Nuestro objetivo es caracterizar las soluciones de voriconazol elaboradas para nebulización y describir su uso en nuestro centro. Método estudio observacional retrospectivo incluyendo pacientes que reciben voriconazol nebulizado para el tratamiento de enfermedades pulmonares (infecciones fúngicas o colonizaciones). La solución de voriconazol se preparó a partir de los viales comerciales para la administración intravenosa. Resultados el pH y la osmolaridad de las soluciones de voriconazol fueron adecuados para su nebulización. Se incluyeron 10 pacientes, 9 adultos y un niño. La dosis fue de 40 mg en los adultos y 10 mg en el paciente pediátrico, diluido a 10 mg/ml, administrados cada 12-24 horas. La duración mediana del tratamiento fue de 139 (rango: 26-911) días. No se reportaron efectos adversos y no se detectó voriconazol en plasma cuando se administró únicamente vía nebulizada. Conclusiones la nebulización de voriconazol es bien tolerada y no se absorbe hacia la circulación sistémica. Son necesarios más estudios de investigación para evaluar su eficacia (AU)

Objective Pulmonary administration of voriconazole involves advantages, including optimization of lung penetration and reduction of adverse effects and interactions. However, there is scarce evidence about its use and there are no commercial presentations for nebulization. We aim to characterize a compounded voriconazole solution for nebulization and describe its use in our center. Method This is a retrospective observational study including patients who received nebulized voriconazole to treat fungal lung diseases (infection or colonization). Voriconazole solution was prepared from commercial vials for intravenous administration. Results The pH and osmolarity of voriconazole solutions were adequate for nebulization. Ten patients were included, nine adults and a child. The dosage was 40 mg in adults and 10 mg in the pediatric patient, diluted to a final concentration of 10 mg/ml, administered every 12-24 hours. The median duration of treatment was 139 (range: 26-911) days. There were no reported adverse effects and the drug was not detected in plasma when nebulized only. Conclusion Voriconazole nebulization is well tolerated and it is not absorbed into the systemic circulation; further research is needed to assess its efficacy (AU)

Characterization and real-live results of nebulized voriconazole: A single-center observational study.

OBJECTIVE: Pulmonary administration of voriconazole involves advantages, including optimization of lung penetration and reduction of adverse effects and interactions. However, there is scarce evidence about its use and there are no commercial presentations for nebulization. We aim to characterize a compounded voriconazole solution for nebulization and describe its use in our center. METHOD: This is a retrospective observational study including patients who received nebulized voriconazole to treat fungal lung diseases (infection or colonization). Voriconazole solution was prepared from commercial vials for intravenous administration. RESULTS: The pH and osmolarity of voriconazole solutions were adequate for nebulization. Ten patients were included, 9 adults and a child. The dosage was 40 mg in adults and 10 mg in the pediatric patient, diluted to a final concentration of 10 mg/ml, administered every 12-24 h. The median duration of treatment was 139 (range: 26-911) days. There were no reported adverse effects and the drug was not detected in plasma when nebulized only. CONCLUSION: Voriconazole nebulization is well-tolerated and it is not absorbed into the systemic circulation; further research is needed to assess its efficacy.

Characterization and real-live results of nebulized voriconazole: A single-center observational study. / [Artículo traducido] Caracterización y resultados del uso de voriconazol nebulizado en un entorno real: un estudio observacional unicéntrico.

OBJECTIVE: Pulmonary administration of voriconazole involves advantages, including optimization of lung penetration and reduction of adverse effects and interactions. However, there is scarce evidence about its use and there are no commercial presentations for nebulization. We aim to characterize a compounded voriconazole solution for nebulization and describe its use in our center. METHOD: This is a retrospective observational study including patients who received nebulized voriconazole to treat fungal lung diseases (infection or colonization). Voriconazole solution was prepared from commercial vials for intravenous administration. RESULTS: The pH and osmolarity of voriconazole solutions were adequate for nebulization. Ten patients were included, nine adults and a child. The dosage was 40 mg in adults and 10 mg in the pediatric patient, diluted to a final concentration of 10 mg/ml, administered every 12-24 hours. The median duration of treatment was 139 (range: 26-911) days. There were no reported adverse effects and the drug was not detected in plasma when nebulized only. CONCLUSION: Voriconazole nebulization is well tolerated and it is not absorbed into the systemic circulation; further research is needed to assess its efficacy.

Estabilidad del colirio de insulina para el tratamiento de úlceras corneales refractarias / Stability of insulin eye drops in the treatment of refractory corneal ulcers

Objetivo: Determinar y comparar la estabilidad físico-química y microbiológica de dos colirios de insulina 25 UI/ml elaborados con suerofisiológico o balanced salt solution bajo diferentes condiciones de conservación durante 120 días.Método: Los colirios se elaboraron por triplicado con insulina Actrapid®100 Ul/ml y balanced salt solution o suero fisiológico como vehículo, yfueron conservados a temperatura ambiente (25 °C), en nevera (2-8 °C)o congelador (–20 °C) durante 120 días. Se determinó la concentraciónde insulina mediante cromatografía liquida de ultra alta resolución, laosmolalidad y el pH a días 0, 3, 7, 15, 30, 60, 90 y 120. Asimismo, seextrajeron muestras para estudios microbiológicos en los días 0, 15, 30,60, 90 y 120.Resultados: La formulación elaborada con suero fisiológico mantuvola concentración de insulina por encima del 90% con respecto a la inicialtras 120 días de estudio en todas las condiciones de temperatura. En elcaso del colirio elaborado con balanced salt solution, la concentraciónse mantuvo estable en ambiente y congelador tras 120 días, aunque ennevera descendió por debajo del 90% a día 90 de estudio. Los valoresde osmolalidad y pH se mantuvieron constantes en ambas formulacionesy condiciones de conservación. No se observó crecimiento microbiológico en ninguna de las muestras retiradas.Conclusiones: El colirio de insulina 25 UI/ml elaborado con suerofisiológico es estable 120 días, conservado tanto a temperatura ambientecomo en nevera o congelador, protegido de la luz. Con balanced saltsolution permanece estable 120 días a temperatura ambiente y congelador, reduciéndose el periodo de validez a 90 días en el caso de laconservación en nevera. (AU)

Objective: To determine and compare the physicochemical and microbiological stability of two 25 IU/mL insulin eye drop formulations madewith normal saline and a balanced salt solution, respectively, stored for120 days under various conditions.Method: Eye drops were compounded in triplicate with 100 IU/mLActrapid® insulin and either normal saline or a balanced salt solution asvehicles, and they were stored alternatively at room temperature (25 °C),in a refrigerator (2-8 °C) or in a freezer (–20 °C) for 120 days. Insulinconcentrations were determined by ultra-high resolution liquid chromatography, and osmolality and pH values were measured at days 0, 3, 7,15, 30, 60, 90 and 120. Likewise, samples were extracted for microbiological studies on days 0, 30, 60, 90 and 120.Results: The formulation made with normal saline maintained insulinconcentrations above 90% of the baseline level after 120 days acrossall temperature conditions. In the case of the balanced salt solution-basedeye drops, insulin concentration when stored at room temperature or inthe freezer remained stable after 120 days, although insulin concentrationwhen stored in the refrigerator fell below 90% on day 90 of the study.Osmolality and pH values remained constant in both formulations andacross all storage conditions. No microbiological growth was observedin any of the samples. Conclusions: 25 IU/mL insulin eye drops made with normal salineremain stable for 120 days whether they are stored at room temperature,in a refrigerator or in a freezer, provided that they are protected fromlight. When made with a balanced salt solution, they remain stable for120 days at room temperature and in a freezer, their shelf life being reduced to 90 days in the case of storage in a refrigerator. (AU)

Formulación magistral en la atención farmacéutica del paciente oncopediátrico / Drug Compounding in Pharmaceutical Care of Oncopediatric Patients

Introducción: El tratamiento farmacológico del paciente oncopediátrico supone una dificultad para el equipo asistencial ya que muchos medicamen-tos registrados por la administración sanitaria no están indicados en población pediátrica, creándo-se un vacío terapéutico en el tratamiento que es cubierto a través de la formulación magistral (FM). El objetivo del estudio es analizar la elaboración de medicamentos individualizados para oncopediatría en los últimos tres años en el Servicio de Farmacia de un hospital de tercer nivel.Métodos: Estudio descriptivo, observacional, retrospectivo de las FM que se elaboraron para el Servicio de Oncopediatría en el periodo 2019-2021. Para cada FM se detalló su indicación y aplicación clínica. En la descripción cuantitativa se especificó número de fórmulas elaboradas y porcentaje. En la descripción cualitativa se detalló principio activo y concentración, procedimiento para elaborar la for-mulación, dosis de principio activo y de excipientes; condiciones de conservación y fecha de caducidad.Resultados: En el periodo de estudio, se elaboraron 3730 FM para el Servicio de Oncopediatría. Las 4 fórmulas magistrales con mayor peso en la prepa-ración son las de los principios activos: etopósido, fenofibrato, ondansetrón y mercaptopurina. El 57,4% de las FM fueron soluciones orales y el 26,5% suspensiones. La aplicación clínica del 71% de las FM preparadas fue el tratamiento de las patologías onco-hematológicas.Conclusiones: En el paciente oncopediátrico, se acentúa la necesidad de una farmacoterapia más individualizada para asegurar una correcta dosifi-cación y adherencia al tratamiento, siendo la FM la herramienta que solventaría sus necesidades terapéuticas (AU)

Introduction: The pharmacological treatment of the oncopediatric patient represents a difficulty for the health care team, since many drugs registered by the health administration are not indicated in the pediatric population, creating a therapeutic gap in the treatment that is covered through the drug compounding (DC). The aim of this study is to analyze the preparation of individualized drugs for oncopediatrics in the last three years in the Phar-macy Service of a tertiary hospital.Methods: It was carried out a descriptive, observa-tional and retrospective study of the DCs that were prepared for the Oncopediatric Service in the period 2019-2021. For each DC, its indication and clinical application were detailed. In the quantitative de-scription, the number of DC elaborated and percent-age were specified. In the qualitative description, active ingredient and concentration, procedure to prepare the formulation, dose of active ingredient, excipients, storage conditions and expiration date were detailed.Results: During the study period, 3730 DC were prepared for the Oncopediatric Service. It is import-ant to note that the 4 formulations with the greatest weight in the preparation were those of the active ingredients: etoposide, fenofibrate, ondansetron and mercaptopurine. Oral solutions and suspen-sions accounted for 57.4% and 26.5% of the DC. The clinical application of 71% of the DC prepared was the treatment of onco-hematological patholo-gies.Conclusions: In the oncopediatric patient, the need for a more individualized pharmacotherapy is accentuated to ensure a correct dosage and adher-ence to treatment, being the DC the tool that would solve its therapeutic needs (AU)

Desarrollo de una crema de carbocisteína10% + urea 5% para el tratamiento tópico de las ictiosis congénitas / Development of a carbocysteine 10% + urea 5% cream for the topical treatment of congenital ichthyosis

Objetivo: Optimización de una fórmula magistral tópica de N-acetilcisteínay urea para el tratamiento tópico de la ictiosis.Método: Se revisó la estructura química de la molécula de N-acetilcisteínay sus procesos metabólicos. Se realizó una búsqueda de posiblesmoléculas alternativas con una estructura química similar a la N-acetilcisteínaque pudiesen mejorar sus propiedades organolépticas. Bases de datos:PubChem®, Botplus®, Centro de Información de Medicamentos de la Agencia Española de Medicamentos y Productos Sanitarios. Criterios de selecciónde la molécula: similitud estructural, mismo grupo terapéutico, mismomecanismo de acción, misma indicación autorizada, ausencia de olordesagradable y estar comercializada como materia prima en España. Parael desarrollo galénico y validación de la fórmula se realizaron varios ensayosy controles siguiendo el procedimiento de elaboración de emulsionesdel Formulario Nacional. Para establecer el periodo de validez se siguieronlas recomendaciones de la “Guía de buenas prácticas de preparación demedicamentos en los servicios de farmacia hospitalaria”.Resultados: La N-acetilcisteína presenta grupo sulfhidrilo libre, responsabledel olor, sufre desacetilación y sus principales metabolitos soncistina y cisteamina. Las moléculas evaluadas fueron: cistina, cisteamina,carbocisteína, cisteína y metionina. Se seleccionó la carbocisteína por cumplir todos los criterios de selección. La carbocisteína es prácticamenteinsoluble en agua y soluble en disoluciones de ácidos minerales e hidróxidosalcalinos. A diferencia de la N-acetilcisteína, carece de olor fétido.Presenta su máxima estabilidad a pH 5,5-7,5. La composición de la fórmulamagistral (100 g): carbocisteína (10 g), urea (5 g), glicerina (15 g),agua (44 ml), hidróxido sódico (1 g) y Neo PCL® Oil/Water (O/W)(25 g). Periodo de caducidad: 30 días.

Objective: Optimization of a topical formula of N-acetylcysteine andurea for the topical treatment of ichthyosis.Method: We reviewed the chemical structure of the N-acetylcysteinemolecule and its metabolic processes. A search was conducted of possiblealternative molecules with a chemical structure similar to that of N-acetylcysteinethat could have improved organoleptic properties. The followingdatabases were used: PubChem®, Botplus®, the Drug Information Centreof the Spanish Agency of Medicines and Medical Devices. The moleculeselection criteria were as follows: structural similarity, same therapeuticgroup, same mechanism of action, same authorized indication, absenceof unpleasant smell, and being marketed as raw material in Spain. To completethe pharmaceutical development and validation of the compound,several tests and controls were conducted following the emulsion productionprocedure of the National Formulary. In order to establish the validityperiod, we followed the recommendations of the “Guide to Good DrugPreparation Practices in Hospital Pharmacy Services”.Results: N-acetylcysteine has a free sulfhydryl group, which is responsiblefor its smell, and undergoes deacetylation. Its main metabolites arecystine and cysteamine. The following molecules were assessed: cystine,cysteamine,carbocisteine, cysteine and methionine. Carbocisteine practicallyinsoluble in water and soluble in mineral acids and alkaline hydroxidessolutions. Unlike N-acetylcysteine, it does not have a fetid smell. It reachesits maximum stability at pH 5.5 to 7.5. The composition of the compound(100 g) was as follows: carbocisteine (10 g), urea (5 g), glycerine (15 g),water (44 mL), sodium hydroxide (1 g), and Neo PCL® Oil/Water (O/W)(25 g). It has an expiration period of 30 days. The organoleptic characteristics,emulsion type, and pH remained stable within the established expirationperiod.

Aplicación de las ciclodextrinas como excipientes en productos farmacéuticos: ¿por qué no en formulación magistral? / Use of cyclodextrins as excipients in pharmaceutical products: why not in extemporaneous preparations?

Objetivo: Evaluar la utilización de ciclodextrinas como excipientes enformulación magistral desde el punto de vista galénico, biofarmacéuticofarmacocinético,toxicológico, regulatorio, económico y comercial.Método: Búsqueda bibliográfica de artículos de revisión y originalescon alto índice de citas, consulta de documentos regulatorios y legislativosy de farmacopeas de reconocido prestigio.Resultados: La solubilidad, la resistencia a la hidrólisis y la eficienciade complejación varían según la ciclodextrina y el fármaco que se pretendecomplejar. En algunos casos es necesario añadir excipientes paramejorar la eficiencia de complejación. Los procesos de complejación defármacos con ciclodextrinas a nivel de laboratorio son poco robustos yademás existe mucha variabilidad para una misma ciclodextrina entreproveedores y lotes de un mismo proveedor, requiriéndose más controlesen las fórmulas elaboradas. La estabilidad de los complejos ciclodextrinas-fármaco puede alterar la biodisponibilidad oral de los fármacos.Además, algunas ciclodextrinas optimizan la permeabilidad a través demembranas biológicas específicas y el tiempo de contacto con las mismas.Aunque son seguras, superados determinados umbrales de dosis ytiempos de administración pueden producir efectos secundarios. Solo lasciclodextrinas que están reconocidas como excipientes en farmacopeaspueden utilizarse en formulación magistral. Las ciclodextrinas suponen unincremento del coste en formulación magistral y su adquisición a través deproveedores reconocidos no es siempre posible.Conclusiones: A pesar de sus interesantes propiedades como excipientesderivadas de la formación de complejos de inclusión, la necesidadde mayores controles de calidad, estudiar constantes de estabilidad, sualto coste y difícil adquisición pueden explicar por qué la utilización deciclodextrinas en formulación magistral no se considera una alternativaviable en la actualidad.

Objective: To conduct an assessment of cyclodextrins used as excipientsin pharmaceutical formulations, considering compounding, biopharmaceuticalpharmacokinetic,toxicological, regulatory, economic and commercial aspects.Methods: A literature search was performed of highly cited review andoriginal articles. Regulatory and legislative documents and well-establishedpharmacopoeias were also consulted.Results: Solubility, resistance to hydrolysis and complexation efficiencyare variables that depend on the cyclodextrin itself and on the drug to becomplexed. In some cases, addition of excipients is necessary to improvecomplexation efficiency. Complexation of drugs with cyclodextrins atlaboratory scale tends to be rather inconsistent. Moreover, wide variationsexist for the same cyclodextrin across different suppliers and evenacross batches from the same supplier. This means more control analysesmust be carried out of pharmaceutical preparations. Problems with thestability of cyclodextrin-drug complexes could affect the oral bioavailabilityof the drugs. Additionally, some cyclodextrins may optimize the drug’spermeability through specific biological membranes and the length of timeit remains in contact with them. Despite the safety profile of cyclodextrins,exceeding certain dosing thresholds and administration times might causeadverse effects. Only cyclodextrins recognized as excipients by well-established pharmacopeias should be used in pharmaceutical compounding.Cyclodextrins lead to an increase in the global costs of compounding andtheir purchase through recognized suppliers is often unfeasible.Conclusions: Despite their interesting properties as excipients due toinclusion complex formation, the need to carry out more quality controlanalyses and stability constant studies, combined with the high cost anddifficulty to purchase cyclodextrins, may explain why their use in pharmaceuticalcompounding is currently not a viable alternative.

Medicamentos de elaboración o preparación no industrial: una nueva propuesta de clasificación / Non-industrially elaborated or prepared drugs: a new classification proposal

Introducción: Ni el legislador, ni los diferentes estudios previos han establecido una clasificación exhaustiva de los medicamentos de elaboración o preparación no industrial en el territorio regulatorio español. Métodos: Revisión bibliográfica sobre la normativa (nacional y comunitaria) y estudios doctrinales relativos al marco jurídico de los medicamentos de uso humano, y el análisis de la misma. Resultados: En la literatura no se encuentra una clasificación adecuada de los medicamentos de elaboración o preparación no industrial. Conclusiones: Se ha propuesto una clasificación doctrinal de los medicamentos de elaboración o preparación no industrial basada en cuatro categorías principales. (AU)

Introduction: Neither the legislator nor the different previous studies have established an exhaustive classification of non-industrially elaborated or prepared drugs in the Spanish regulatory territory. Method: Bibliographic review on the regulations (national and community) and doctrinal studies related to the legal framework of medicines for human use, and their analysis. Results: There is no adequate classification of non-industrially elaborated or prepared drugs in the literature. Conclusions: A doctrinal classification of non-industrially elaborated or prepared drugs has been proposed based on four main categories

The Most Useful Pharmaceutical Formulations (Individualized Medications) in Pediatric Dermatology: A Review. / Revisión de las fórmulas magistrales (medicamentos individualizados) de mayor interés en dermatología pediátrica.

The administration of appropriate doses of active ingredients and excipients is crucial for achieving desired treatment outcomes in pediatric dermatology. A number of factors need to be considered, including the characteristics of the lesion, the patient, and the drug. An additional challenge in pediatric settings is the limited number of commercially available formulations suitable for use in children. Drug compounding, which is the preparation of medications tailored to the needs of individual patients, is a good alternative for pediatric populations for a number of reasons. Using a customized compound, the clinician can prescribe formulations that contain the optimal dose of the active ingredients within acceptable limits and the most suitable vehicle and formulation components. Compounding can also be used to combine several active ingredients in a single medication and even adapt the vehicle to the characteristics of the lesion and the needs of the patient. The pharmaceutical formulations described in this review are based on extensive clinical experience and can be customized to meet individual needs.

Drug Compounding for Diseases of the Oral Mucosa. / Formulación magistral en patología de la mucosa oral.

Commercial topical medications for oral conditions are scarce and the vehicles used are not very suitable. Therefore, formulations containing active ingredients in vehicles specially designed for oral application must often be prepared. Drug compounding offers other advantages, including the possibility of combining several active ingredients in a single vehicle and prescribing drugs that are in short supply. In this article, we describe the main pharmaceutical formulations used to treat the most common diseases of the oral mucosa.

[Recommendations for the preparation and administration of antituberculosis drugs in children. Second phase of the Magistral Project of the Spanish Network for the Study of Paediatric Tuberculosis (pTBred)]. / Recomendaciones para la elaboración y administración de fármacos antituberculosos en niños. Segunda fase del Proyecto Magistral de la Red Española de Estudio de la Tuberculosis Pediátrica (pTBred).

The Spanish Network for the Study of Paediatric Tuberculosis has shown a lack of national consensus on the treatment of tuberculosis in children, partly due to the unavailability of paediatric presentations of antituberculosis drugs. The harmonisation of tuberculosis treatment in children is a priority in Spain. A joint action is proposed by a group of Spanish experts in childhood tuberculosis and in the area of Paediatric Pharmacology. To this end, a pTBred-led workgroup of members from five scientific bodies has been created. Drug pharmaceutical compounding in oral suspensions or oral solutions are recommended as follows: isoniazid 50mg/mL, pyrazinamide 100mg/mL, and ethambutol 50mg/mL. Raw materials, period of validity, and storage conditions are specified. Recommendations for the use of fixed-dose combination drugs are also established. If oral solutions/suspensions or fixed-dose combination drugs are not appropriate, the use of crushed tablets is recommended. Adherence to treatment and optimal dosing of antituberculosis drugs are critical in the control and eradication of TB. This multidisciplinary document provides an opportunity to promote the appropriate treatment of paediatric tuberculosis in Spain, and should become a useful tool for paediatricians and pharmacists.

[The challenge of administering anti-tuberculosis treatment in infants and pre-school children. pTBred Magistral Project]. / El reto de la administración de antituberculosos en lactantes y preescolares. Proyecto Magistral de pTBred.

INTRODUCTION: There are no paediatric formulations of anti-tuberculous drugs in Spain, with the only exception being rifampicin. Some paediatricians often prescribe composite formulations (CF), while others prefer to give crushed tablets. Nevertheless, there is no consensus in this regard, or any pharmacokinetic studies validating these procedures. In this situation, the Spanish Network for the Study of Paediatric Tuberculosis (pTBred) has launched the Magistral Project, which has as its first phase aims to analyse the desirability of developing child-friendly pharmaceutical formulations and other aspects regarding the anti-tuberculous drug prescription in children. MATERIAL AND METHODS: A cross-sectional, multicentre, nationwide study was conducted, based on an online questionnaire sent to members of pTBred between February and March 2015. RESULTS: Fifty-four responses from 67 consulted institutions were received. Most of the respondents reported prescribing crushed tablets. A significant number of those surveyed, although being fewer, prescribe CF, for which availability varies widely among institutions. Eighty-three percent replied that it would be essential to have fixed dose combinations of anti-tuberculous drugs, specifically adapted to paediatric doses and administered by CF or tablets. Among the surveyed institutions, differences were found in the management of latent tuberculosis infection, in the use of directly observed therapy, and in the monitoring of adverse events. CONCLUSIONS: Our survey reveals great diversity in anti-tuberculous drug prescription in children, due to the lack of suitable infant formulations, which could have an impact on treatment adherence and outcomes. pTBred intends to develop a pioneering and useful consensus document on the management of anti-tuberculous medication in children.

Compounding as a current therapeutic option in dermatology.

Compounding continues to play a key role in the treatment of skin conditions, despite the abundance of products made by the pharmaceutical industry. Right from the earliest days of dermatology, compounding proved very useful in the treatment of diseases for which no specific drugs were available. However, as new products came onto the market, this usefulness was called into question, and doubts over safety, stability, and effectiveness were raised. Today, compounding is regaining the place it once held in routine dermatological practice. We review the advantages and disadvantages of compounding, the most common indications, current legislation in our setting, and the latest developments in active ingredients and vehicles.

Estudio comparativo de estabilidad de tres formulaciones magistrales de Sildenafil bajo la forma de solución, obtenidas a partir de diferentes productos comerciales / Comparative study stability of the three master formulation of Sildenafil solution obtained from differents trademarks

El Sildenafil es un fármaco de comprobada actividad terapéutica en la disfunción eréctil; se encuentra disponible bajo la forma farmacéutica de tabletas de administración oral. En la actualidad se está formulando magistralmente en forma de so lución oral a una concentración de 1mg/ml, para la hipertensión pulmonar (HP), por lo que se ha planteado realizar un estudio de la estabilidad en tres condiciones: ambientales (25±-2 ºC), de refrigeración (5±3 ºC) y exageradas de almacenamiento (40 ºC ± 2 ºC). Los parámetros evaluados fueron apariencia, limpidez, densidad, pH y contenido de sildenafil. El método analítico empleado fue cromatografía líquida de alta resolución (HPLC) de fase reversa. La apariencia, los valores de pH y densidad de las soluciones obtenidas se mostraron sin cambios significativos, en las diferentes muestras y condiciones de estudio. En cuanto a los resultados del contenido inicial de sildenafil se obtuvo aproximadamente el 75% en peso al formular la solución, partiendo del comprimido. Cabe señalar que se observó discrepancia en los valores de concentración del sildenafil obtenidos en los diferentes tiempos y condiciones; resultados éstos de esperarse por tratarse de una formulación magistral que parte de comprimidos de diferentes casas comerciales, por lo que este estudio permitió sugerir que la formulación magistral se reformule a la forma farmacéutica de suspensión, para garantizar el contenido de todo el principio activo en la misma.

Sildenafil is a drug with proven therapeutic activity in erectile dysfunction is available under the pharmaceutical form of tablets for oral administration. It is currently being de veloped skillfully in an oral solution at a concentration of 1mg/ml, for pulmonary hypertension (pH), as has been planned to perform a study of stability in three conditions: environmental (25 ± 2 ºC), refrigeration (5 ± 3 ºC) and exaggerated storage (40 °C ± 2 ºC). The parameters evaluated were appearance, clarity, density, pH and content of sildenafil. The analytical method used was high performance liquid chromatography (HPLC) reverse phase. The appearance, pH and density of the solutions were no significant changes in the different samples and study conditions. As for the results of the initial content of sildenafil was obtained about 75% by weight in for mulating the solution, based on the tablet. It should be noted that there was discrepancy in the values of concentration of sildenafil obtained at different times and conditions, results they expected because it is a masterly formulation of tablets of different business houses, so this study suggest that the wording allowed masterful be reformulated to the pharmaceutical form of suspension, to ensure the contents of the entire active.